Evidence map›Paper›PMID 37366919›Full record

ArticleCurrent oncology (Toronto, Ont.)2023

Integrated Analysis of the RASH Study with the Use of the "Burden of Therapy" (BOTh

Klara Dorman, Stefan Boeck, Robert J Snijder, Jens T Siveke, Michael Schenk, Julia Mayerle, Karel Caca, Jens Freiberg-Richter, Ludwig Fischer von Weikersthal, Frank Kullmann and 11 more

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Current oncology (Toronto, Ont.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01729481 (Phase II Study to Evaluatate the Efficacy of Gemcitabine Plus Erlotinib for RASH-positive Patients With Metastatic Pancreatic Cancer and Friendly Risk Circumstances), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01729481 phase2unknown statusnot on this map

Phase II Study to Evaluatate the Efficacy of Gemcitabine Plus Erlotinib for RASH-positive Patients With Metastatic Pancreatic Cancer and Friendly Risk Circumstances

TypeinterventionalSponsorLudwig-Maximilians - University of MunichRan2012 to 2017Enrolled150ConditionsMetastatic Pancreatic AdenocarcinomaArmsGemcitabine, Erlotinib, Oxaliplatin, Folinic Acid, Irinotecan
3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 14 institutions in 1 country.

Klara DormanDepartment of Medicine III and Comprehensive Cancer Center, University Hospital, Ludwig Maximilian University of Munich, Marchioninistr. 15, 81377 Munich, Germany.
Stefan BoeckDepartment of Medicine III and Comprehensive Cancer Center, University Hospital, Ludwig Maximilian University of Munich, Marchioninistr. 15, 81377 Munich, Germany.ORCID 0000-0002-1922-2127
Robert J SnijderBOTh Analytics GmbH, 80687 Munich, Germany.
Jens T SivekeBridge Institute of Experimental Tumor Therapy, West German Cancer Center, University Hospital Essen, 45147 Essen, Germany.ORCID 0000-0002-8772-4778
Michael SchenkDepartment of Haematology and Oncology, Hospital Barmherzige Brüder, 93049 Regensburg, Germany.
Julia MayerleDepartment of Internal Medicine II, University Hospital, LMU Munich, 81377 Munich, Germany.
Karel CacaDepartment of Internal Medicine I, Klinikum Ludwigsburg, 71640 Ludwigsburg, Germany.
Jens Freiberg-RichterPractice for Haematology and Oncology, 01307 Dresden, Germany.
Ludwig Fischer von WeikersthalDepartment of Oncology, Gesundheitszentrum St. Marien, 92224 Amberg, Germany.
Frank KullmannDepartment of Medicine I, Klinikum Weiden, 92637 Weiden, Germany.ORCID 0000-0001-5575-1010
Anke Reinacher-SchickDepartment of Haematology and Oncology, St. Josef-Hospital, Ruhr University, 44791 Bochum, Germany.
Martin FuchsDepartment of Gastroenterology, Hepatology and Gastrointestinal Oncology, Klinikum Bogenhausen, 81925 Munich, Germany.
Stephan KanzlerDepartment of Internal Medicine II, Leopoldina Krankenhaus Schweinfurt, 97422 Schweinfurt, Germany.
Volker KunzmannDepartment of Medical Oncology, University Hospital of Wuerzburg, 97080 Wuerzburg, Germany.
Thomas J EttrichDepartment of Internal Medicine I, University of Ulm, 89081 Ulm, Germany.ORCID 0000-0002-7654-2442
Danmei ZhangDepartment of Medicine III and Comprehensive Cancer Center, University Hospital, Ludwig Maximilian University of Munich, Marchioninistr. 15, 81377 Munich, Germany.ORCID 0000-0001-6048-4711
Swantje HeldClinAssess GmbH, Department of Biometry, 51379 Leverkusen, Germany.
Ayad Abdul-AhadBOTh Analytics GmbH, 80687 Munich, Germany.
Michael von Bergwelt-BaildonDepartment of Medicine III and Comprehensive Cancer Center, University Hospital, Ludwig Maximilian University of Munich, Marchioninistr. 15, 81377 Munich, Germany.
Volker HeinemannDepartment of Medicine III and Comprehensive Cancer Center, University Hospital, Ludwig Maximilian University of Munich, Marchioninistr. 15, 81377 Munich, Germany.
Michael HaasDepartment of Medicine III and Comprehensive Cancer Center, University Hospital, Ludwig Maximilian University of Munich, Marchioninistr. 15, 81377 Munich, Germany.
Deutschen Konsortium für Translationale Krebsforschung · DELudwig-Maximilians-Universität München · DEGerman Cancer Research Center · DEKlinikum Ludwigsburg · DEKlinikum St. Marien Amberg · DEKlinikum Weiden · DEKrankenhaus Barmherzige Brüder · DELeopoldina Krankenhaus Schweinfurt · DELMU Klinikum · DEMünchen Klinik Bogenhausen · DESt. Josef-Hospital · DEUniversitätsklinikum Würzburg · DEUniversität Ulm · DEZimmer Biomet (Germany) · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This analysis of the RASH trial (NCT01729481) aimed at gaining a better understanding of the "Burden of Therapy" (BOTh

Indexed as

ExanthemaPancreatic NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsClinical Trials as TopicErlotinib HydrochlorideHumansErlotinib Hydrochlorideburden of therapyerlotinibFOLFIRINOXgemcitabinepancreatic cancerquality of liferash

Identifiers

PMID37366919
PMCPMC10297548
OpenAlexW4381191516

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.